Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 38,500 Shares

Posted by Geri Gentry on Sep 9th, 2026

Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) major shareholder Bioventures 2018 L.P. Mpm sold 38,500 shares of the company’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $7.11, for a total transaction of $273,735.00. Following the completion of the transaction, the insider owned 4,106,452 shares of the company’s stock, valued at $29,196,873.72. This trade represents a 0.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Bioventures 2018 L.P. Mpm also recently made the following trade(s):

On Wednesday, September 9th, Bioventures 2018 L.P. Mpm sold 28,837 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.13, for a total transaction of $205,607.81.
On Tuesday, September 8th, Bioventures 2018 L.P. Mpm sold 192,500 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.41, for a total transaction of $1,426,425.00.
On Thursday, September 3rd, Bioventures 2018 L.P. Mpm sold 32,263 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.17, for a total value of $231,325.71.
On Wednesday, September 2nd, Bioventures 2018 L.P. Mpm sold 25,131 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.19, for a total value of $180,691.89.
On Tuesday, September 1st, Bioventures 2018 L.P. Mpm sold 29,088 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.06, for a total transaction of $205,361.28.
On Monday, August 31st, Bioventures 2018 L.P. Mpm sold 44,259 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.99, for a total transaction of $309,370.41.
On Friday, August 28th, Bioventures 2018 L.P. Mpm sold 3,733 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.01, for a total value of $26,168.33.
On Thursday, August 27th, Bioventures 2018 L.P. Mpm sold 38,922 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.20, for a total value of $280,238.40.

Entrada Therapeutics Stock Performance

Shares of NASDAQ TRDA traded down $0.41 during midday trading on Wednesday, hitting $7.11. 381,776 shares of the company traded hands, compared to its average volume of 247,577. Entrada Therapeutics, Inc. has a 12-month low of $5.02 and a 12-month high of $16.45. The firm has a market cap of $276.86 million, a P/E ratio of -1.80 and a beta of -0.25. The stock has a 50-day moving average price of $7.05 and a 200 day moving average price of $9.09.

Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The business had revenue of $0.90 million for the quarter, compared to the consensus estimate of $2.32 million. Entrada Therapeutics had a negative net margin of 3,537.73% and a negative return on equity of 57.61%. As a group, equities analysts expect that Entrada Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Analysts Set New Price Targets

TRDA has been the subject of a number of research analyst reports. Wall Street Zen raised Entrada Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Guggenheim reduced their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Roth Capital reiterated a “buy” rating and set a $11.00 target price on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. Finally, Weiss Ratings raised shares of Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 31st. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.75.

Read Our Latest Research Report on TRDA

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TRDA. 5AM Venture Management LLC purchased a new position in shares of Entrada Therapeutics during the second quarter worth about $29,854,949. BlackRock Inc. acquired a new position in shares of Entrada Therapeutics during the second quarter worth $19,013,000. Millennium Management LLC increased its stake in Entrada Therapeutics by 391.2% during the 3rd quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock worth $4,852,000 after buying an additional 666,287 shares during the period. Nantahala Capital Management LLC acquired a new stake in shares of Entrada Therapeutics during the second quarter valued at about $2,212,232. Finally, Citadel Advisors LLC raised its stake in shares of Entrada Therapeutics by 234.5% during the third quarter. Citadel Advisors LLC now owns 335,741 shares of the company’s stock valued at $1,947,000 after purchasing an additional 235,384 shares in the last quarter. 86.39% of the stock is currently owned by institutional investors and hedge funds.

About Entrada Therapeutics

(Get Free Report)

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.